Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: MDXXF )

0.2175 +0.0130 (+6.36%)
Streaming Delayed Price Updated: 10:52 AM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MDXXF

PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial
PharmAla Biotech will supply GMP LaNeo MDMA to Mt. Sinai Health System for clinical research, advancing therapy for neurological disorders. 
Via Benzinga
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
From PharmAla Biotech
Via GlobeNewswire
PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial
PharmAla Biotech will supply the University of Texas, San Antonio with a novel LaNeo MDMA dosage form for a clinical trial, advancing MDMA research and innovation. 
Via Benzinga
PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial
PharmAla Biotech to supply MDMA for a clinical trial at Harvard's Maclean Hospital. Company also explores European distribution at CPHI Milan Conference. 
Via Benzinga
PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract
PharmAla Biotech partners with Johns Hopkins to supply MDMA for clinical trials, terminates contract with Red Light Holland, and presents new APA-01 research at the EBPS Workshop. 
Via Benzinga
PharmAla Launches MDMA Clinical Trial Tool for Researchers
From PharmAla Biotech
Via GlobeNewswire
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
From PharmAla Biotech
Via GlobeNewswire
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
Red Light Holland and PharmAla achieve psilocybin extraction milestone, advancing API development for scalable medical products. Read now! 
Via Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
From PharmAla Biotech
Via GlobeNewswire
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
From PharmAla Biotech
Via GlobeNewswire
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
Via Benzinga
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications 
From PharmAla Biotech
Via GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market 
From PharmAla Biotech
Via GlobeNewswire
Truffles To Market: Red Light Holland Wants To Develop Psilocybin API At Scale
Via Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.